UroGen Pharma’s (URGN) Buy Rating Reiterated at Guggenheim
Guggenheim restated their buy rating on shares of UroGen Pharma (NASDAQ:URGN – Free Report) in a research report released on Tuesday,Benzinga reports. A number of other research analysts have also weighed in on URGN. Scotiabank started coverage on UroGen Pharma in a research note on Wednesday, April 16th. They set a “sector outperform” rating and […]
Guggenheim restated their buy rating on shares of UroGen Pharma (NASDAQ:URGN – Free Report) in a research report released on Tuesday,Benzinga reports. A number of other research analysts have also weighed in on URGN. Scotiabank started coverage on UroGen Pharma in a research note on Wednesday, April 16th. They set a “sector outperform” rating and […]
